CA2710494A1 - Modeles murins portant une mutation du type inactivation du gene de la glutaminyl cyclase - Google Patents

Modeles murins portant une mutation du type inactivation du gene de la glutaminyl cyclase Download PDF

Info

Publication number: CA2710494A1
Authority: CA; Canada
Prior art keywords: qpct; gene; human animal; pcr; knock
Prior art date: 2008-01-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2710494A

Other languages

English (en)

Inventor

Hans-Ulrich Demuth

Torsten Hoffmann

Stephan Schilling

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vivoryon Therapeutics AG

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-14

Filing date

2009-01-14

Publication date

2009-07-23

2009-01-14 Application filed by Individual filed Critical Individual

2009-07-23 Publication of CA2710494A1 publication Critical patent/CA2710494A1/fr

Status Abandoned legal-status Critical Current

Links

230000035772 mutation Effects 0.000 title claims abstract description 44
108010081484 glutaminyl-peptide cyclotransferase Proteins 0.000 title abstract description 19
238000010172 mouse model Methods 0.000 title description 6
238000000034 method Methods 0.000 claims abstract description 130
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 68
201000010099 disease Diseases 0.000 claims abstract description 62
241001465754 Metazoa Species 0.000 claims description 191
108700028369 Alleles Proteins 0.000 claims description 145
238000012216 screening Methods 0.000 claims description 134
108020004414 DNA Proteins 0.000 claims description 121
230000000694 effects Effects 0.000 claims description 98
101150035356 Qpct gene Proteins 0.000 claims description 78
150000001875 compounds Chemical class 0.000 claims description 71
238000012360 testing method Methods 0.000 claims description 68
108090000623 proteins and genes Proteins 0.000 claims description 64
241000699666 Mus <mouse, genus> Species 0.000 claims description 61
241000699670 Mus sp. Species 0.000 claims description 58
108090000765 processed proteins & peptides Proteins 0.000 claims description 57
238000010171 animal model Methods 0.000 claims description 54
102000004196 processed proteins & peptides Human genes 0.000 claims description 49
208000024827 Alzheimer disease Diseases 0.000 claims description 38
108700024394 Exon Proteins 0.000 claims description 37
239000003795 chemical substances by application Substances 0.000 claims description 35
230000014509 gene expression Effects 0.000 claims description 33
239000003112 inhibitor Substances 0.000 claims description 32
239000003814 drug Substances 0.000 claims description 28
238000001727 in vivo Methods 0.000 claims description 25
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 24
201000001320 Atherosclerosis Diseases 0.000 claims description 24
241001529936 Murinae Species 0.000 claims description 21
230000015572 biosynthetic process Effects 0.000 claims description 20
230000004770 neurodegeneration Effects 0.000 claims description 19
208000023697 ABri amyloidosis Diseases 0.000 claims description 18
201000010374 Down Syndrome Diseases 0.000 claims description 18
201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims description 18
102100040243 Microtubule-associated protein tau Human genes 0.000 claims description 18
208000037803 restenosis Diseases 0.000 claims description 18
206010039073 rheumatoid arthritis Diseases 0.000 claims description 18
208000017227 ADan amyloidosis Diseases 0.000 claims description 16
201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims description 16
230000002265 prevention Effects 0.000 claims description 15
208000010877 cognitive disease Diseases 0.000 claims description 14
208000027061 mild cognitive impairment Diseases 0.000 claims description 14
238000002360 preparation method Methods 0.000 claims description 14
206010033645 Pancreatitis Diseases 0.000 claims description 13
230000003247 decreasing effect Effects 0.000 claims description 10
230000005764 inhibitory process Effects 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 9
230000035790 physiological processes and functions Effects 0.000 claims description 7
229940124597 therapeutic agent Drugs 0.000 claims description 7
238000006555 catalytic reaction Methods 0.000 claims description 6
208000035475 disorder Diseases 0.000 claims description 5
206010061218 Inflammation Diseases 0.000 claims description 4
230000001668 ameliorated effect Effects 0.000 claims description 4
230000035605 chemotaxis Effects 0.000 claims description 4
230000004054 inflammatory process Effects 0.000 claims description 4
238000012544 monitoring process Methods 0.000 claims description 4
CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 claims description 4
238000013279 ApoE knockout mouse model Methods 0.000 claims description 3
208000009386 Experimental Arthritis Diseases 0.000 claims description 3
239000013543 active substance Substances 0.000 claims description 3
238000011552 rat model Methods 0.000 claims description 3
238000007876 drug discovery Methods 0.000 claims description 2
241001323319 Psen Species 0.000 claims 2
239000000203 mixture Substances 0.000 abstract description 26
102000003642 glutaminyl-peptide cyclotransferase Human genes 0.000 abstract description 17
210000004027 cell Anatomy 0.000 description 187
239000013615 primer Substances 0.000 description 94
239000013598 vector Substances 0.000 description 82
230000001404 mediated effect Effects 0.000 description 60
230000008685 targeting Effects 0.000 description 59
229930193140 Neomycin Natural products 0.000 description 51
229960004927 neomycin Drugs 0.000 description 51
238000002105 Southern blotting Methods 0.000 description 47
238000001514 detection method Methods 0.000 description 45
230000003321 amplification Effects 0.000 description 41
238000003199 nucleic acid amplification method Methods 0.000 description 41
239000000047 product Substances 0.000 description 41
238000009395 breeding Methods 0.000 description 39
230000001488 breeding effect Effects 0.000 description 39
238000002744 homologous recombination Methods 0.000 description 37
230000006801 homologous recombination Effects 0.000 description 37
102000004190 Enzymes Human genes 0.000 description 31
108090000790 Enzymes Proteins 0.000 description 31
239000012636 effector Substances 0.000 description 31
239000012634 fragment Substances 0.000 description 29
239000000523 sample Substances 0.000 description 29
210000001519 tissue Anatomy 0.000 description 28
238000006243 chemical reaction Methods 0.000 description 27
238000011740 C57BL/6 mouse Methods 0.000 description 26
238000012217 deletion Methods 0.000 description 26
230000037430 deletion Effects 0.000 description 26
238000003205 genotyping method Methods 0.000 description 25
238000005755 formation reaction Methods 0.000 description 21
238000001574 biopsy Methods 0.000 description 20
210000002459 blastocyst Anatomy 0.000 description 20
230000007170 pathology Effects 0.000 description 20
238000004520 electroporation Methods 0.000 description 19
229920001184 polypeptide Polymers 0.000 description 19
239000013641 positive control Substances 0.000 description 19
206010068051 Chimerism Diseases 0.000 description 18
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 18
238000011161 development Methods 0.000 description 18
230000018109 developmental process Effects 0.000 description 18
239000000758 substrate Substances 0.000 description 18
235000018102 proteins Nutrition 0.000 description 17
102000004169 proteins and genes Human genes 0.000 description 17
101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 16
230000029087 digestion Effects 0.000 description 16
238000011813 knockout mouse model Methods 0.000 description 16
230000001105 regulatory effect Effects 0.000 description 16
238000007363 ring formation reaction Methods 0.000 description 16
230000010354 integration Effects 0.000 description 15
102100029846 Glutaminyl-peptide cyclotransferase Human genes 0.000 description 14
101000585315 Homo sapiens Glutaminyl-peptide cyclotransferase Proteins 0.000 description 14
241000124008 Mammalia Species 0.000 description 14
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 14
238000000338 in vitro Methods 0.000 description 14
230000004807 localization Effects 0.000 description 14
235000019333 sodium laurylsulphate Nutrition 0.000 description 14
238000007792 addition Methods 0.000 description 13
238000004458 analytical method Methods 0.000 description 13
230000006870 function Effects 0.000 description 13
238000009396 hybridization Methods 0.000 description 13
230000001771 impaired effect Effects 0.000 description 13
150000003839 salts Chemical class 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 12
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 12
235000001014 amino acid Nutrition 0.000 description 12
230000002255 enzymatic effect Effects 0.000 description 12
230000002068 genetic effect Effects 0.000 description 12
210000004602 germ cell Anatomy 0.000 description 12
229910001868 water Inorganic materials 0.000 description 12
229940024606 amino acid Drugs 0.000 description 11
150000001413 amino acids Chemical class 0.000 description 11
230000033228 biological regulation Effects 0.000 description 11
238000010367 cloning Methods 0.000 description 11
238000010276 construction Methods 0.000 description 11
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 11
239000007924 injection Substances 0.000 description 11
PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 11
150000007523 nucleic acids Chemical class 0.000 description 11
238000011144 upstream manufacturing Methods 0.000 description 11
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 10
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 10
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 10
101710155857 C-C motif chemokine 2 Proteins 0.000 description 10
102100021943 C-C motif chemokine 2 Human genes 0.000 description 10
102400001103 Neurotensin Human genes 0.000 description 10
101800001814 Neurotensin Proteins 0.000 description 10
230000009471 action Effects 0.000 description 10
239000000969 carrier Substances 0.000 description 10
238000002347 injection Methods 0.000 description 10
230000004048 modification Effects 0.000 description 10
238000012986 modification Methods 0.000 description 10
210000002569 neuron Anatomy 0.000 description 10
102000039446 nucleic acids Human genes 0.000 description 10
108020004707 nucleic acids Proteins 0.000 description 10
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 9
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 9
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 9
238000003556 assay Methods 0.000 description 9
238000009472 formulation Methods 0.000 description 9
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 9
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 9
239000003550 marker Substances 0.000 description 9
239000002773 nucleotide Substances 0.000 description 9
125000003729 nucleotide group Chemical group 0.000 description 9
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 9
108700021111 pyroglutamyl-glutamyl-proline amide Proteins 0.000 description 9
230000002441 reversible effect Effects 0.000 description 9
229960003604 testosterone Drugs 0.000 description 9
229940034199 thyrotropin-releasing hormone Drugs 0.000 description 9
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 9
208000037259 Amyloid Plaque Diseases 0.000 description 8
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
HYZBGWLLSXSYLX-GUBZILKMSA-N Pglu-glu-pro-amide Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1NC(=O)CC1 HYZBGWLLSXSYLX-GUBZILKMSA-N 0.000 description 8
239000002253 acid Substances 0.000 description 8
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 8
125000003275 alpha amino acid group Chemical group 0.000 description 8
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 8
229940088597 hormone Drugs 0.000 description 8
239000005556 hormone Substances 0.000 description 8
239000013642 negative control Substances 0.000 description 8
239000013612 plasmid Substances 0.000 description 8
230000004044 response Effects 0.000 description 8
238000006467 substitution reaction Methods 0.000 description 8
-1 their salts Chemical class 0.000 description 8
229940034208 thyroxine Drugs 0.000 description 8
108010029485 Protein Isoforms Proteins 0.000 description 7
102000001708 Protein Isoforms Human genes 0.000 description 7
ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 7
108010006785 Taq Polymerase Proteins 0.000 description 7
230000005540 biological transmission Effects 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
230000003197 catalytic effect Effects 0.000 description 7
238000012512 characterization method Methods 0.000 description 7
238000013461 design Methods 0.000 description 7
229940079593 drug Drugs 0.000 description 7
230000004927 fusion Effects 0.000 description 7
229930195712 glutamate Natural products 0.000 description 7
238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 7
108091033319 polynucleotide Proteins 0.000 description 7
102000040430 polynucleotide Human genes 0.000 description 7
239000002157 polynucleotide Substances 0.000 description 7
239000002243 precursor Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000002904 solvent Substances 0.000 description 7
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
241000196324 Embryophyta Species 0.000 description 6
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
108700019146 Transgenes Proteins 0.000 description 6
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
239000000872 buffer Substances 0.000 description 6
230000035558 fertility Effects 0.000 description 6
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 6
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 6
230000003862 health status Effects 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
230000001939 inductive effect Effects 0.000 description 6
208000027866 inflammatory disease Diseases 0.000 description 6
210000001161 mammalian embryo Anatomy 0.000 description 6
239000007787 solid Substances 0.000 description 6
241000894007 species Species 0.000 description 6
238000011895 specific detection Methods 0.000 description 6
238000011830 transgenic mouse model Methods 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
241000699660 Mus musculus Species 0.000 description 5
238000012408 PCR amplification Methods 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000002378 acidificating effect Effects 0.000 description 5
230000001154 acute effect Effects 0.000 description 5
239000000654 additive Substances 0.000 description 5
230000027455 binding Effects 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
230000006727 cell loss Effects 0.000 description 5
238000012790 confirmation Methods 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
229910052751 metal Inorganic materials 0.000 description 5
239000002184 metal Substances 0.000 description 5
244000039328 opportunistic pathogen Species 0.000 description 5
230000001817 pituitary effect Effects 0.000 description 5
229940124606 potential therapeutic agent Drugs 0.000 description 5
230000008569 process Effects 0.000 description 5
230000009467 reduction Effects 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
238000012163 sequencing technique Methods 0.000 description 5
238000012301 transgenic model Methods 0.000 description 5
101150037123 APOE gene Proteins 0.000 description 4
102000004400 Aminopeptidases Human genes 0.000 description 4
108090000915 Aminopeptidases Proteins 0.000 description 4
240000006432 Carica papaya Species 0.000 description 4
108010051219 Cre recombinase Proteins 0.000 description 4
102000053602 DNA Human genes 0.000 description 4
101100216294 Danio rerio apoeb gene Proteins 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
102100022033 Presenilin-1 Human genes 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
241000700605 Viruses Species 0.000 description 4
239000012190 activator Substances 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
230000002776 aggregation Effects 0.000 description 4
238000004220 aggregation Methods 0.000 description 4
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
239000000164 antipsychotic agent Substances 0.000 description 4
230000003542 behavioural effect Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
230000007278 cognition impairment Effects 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
230000009849 deactivation Effects 0.000 description 4
230000007812 deficiency Effects 0.000 description 4
238000010586 diagram Methods 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
235000013922 glutamic acid Nutrition 0.000 description 4
239000004220 glutamic acid Substances 0.000 description 4
230000003054 hormonal effect Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
238000000520 microinjection Methods 0.000 description 4
208000015122 neurodegenerative disease Diseases 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
229940043131 pyroglutamate Drugs 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
230000028327 secretion Effects 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000005495 thyroid hormone Substances 0.000 description 4
229940036555 thyroid hormone Drugs 0.000 description 4
238000001890 transfection Methods 0.000 description 4
241001430294 unidentified retrovirus Species 0.000 description 4
238000005406 washing Methods 0.000 description 4
208000030507 AIDS Diseases 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102000006822 Agouti Signaling Protein Human genes 0.000 description 3
108010072151 Agouti Signaling Protein Proteins 0.000 description 3
239000002126 C01EB10 - Adenosine Substances 0.000 description 3
238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
241000484025 Cuniculus Species 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
108010046276 FLP recombinase Proteins 0.000 description 3
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
208000023105 Huntington disease Diseases 0.000 description 3
241000581650 Ivesia Species 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
108010001831 LDL receptors Proteins 0.000 description 3
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 3
102000009151 Luteinizing Hormone Human genes 0.000 description 3
108010073521 Luteinizing Hormone Proteins 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
206010038997 Retroviral infections Diseases 0.000 description 3
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 3
102000011923 Thyrotropin Human genes 0.000 description 3
108010061174 Thyrotropin Proteins 0.000 description 3
206010052779 Transplant rejections Diseases 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
229960005305 adenosine Drugs 0.000 description 3
102000030621 adenylate cyclase Human genes 0.000 description 3
108060000200 adenylate cyclase Proteins 0.000 description 3
229910021529 ammonia Inorganic materials 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
210000001109 blastomere Anatomy 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
210000001175 cerebrospinal fluid Anatomy 0.000 description 3
230000003399 chemotactic effect Effects 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
230000002950 deficient Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
210000003038 endothelium Anatomy 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 3
229960001340 histamine Drugs 0.000 description 3
230000004185 hypothalamic-pituitary-gonadal axis Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229910021645 metal ion Inorganic materials 0.000 description 3
230000005012 migration Effects 0.000 description 3
238000013508 migration Methods 0.000 description 3
230000007137 neurofibrillary pathology Effects 0.000 description 3
210000004498 neuroglial cell Anatomy 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
230000000269 nucleophilic effect Effects 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
230000008506 pathogenesis Effects 0.000 description 3
230000009038 pharmacological inhibition Effects 0.000 description 3
230000007505 plaque formation Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
208000005069 pulmonary fibrosis Diseases 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
201000002793 renal fibrosis Diseases 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
201000000980 schizophrenia Diseases 0.000 description 3
230000007017 scission Effects 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
210000000278 spinal cord Anatomy 0.000 description 3
230000001629 suppression Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
230000009261 transgenic effect Effects 0.000 description 3
230000007306 turnover Effects 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
238000010200 validation analysis Methods 0.000 description 3
YZJSUQQZGCHHNQ-BYPYZUCNSA-N (2s)-6-amino-2-azaniumyl-6-oxohexanoate Chemical group OC(=O)[C@@H](N)CCCC(N)=O YZJSUQQZGCHHNQ-BYPYZUCNSA-N 0.000 description 2
RINPOXNCRXGFAV-FNXAHOOKSA-N (2s,4s,5r,6r)-5-amino-2-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-amino-5-hydroxy-6-(hydroxymethyl)-4-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-6-[(e)-2-amino-3-hydroxyicos-4-enoxy]-4,5-dihydroxy-2-(h Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(N)C(O)/C=C/CCCCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](N)[C@@H](O)C2)C(O)C(O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RINPOXNCRXGFAV-FNXAHOOKSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
102400000345 Angiotensin-2 Human genes 0.000 description 2
101800000733 Angiotensin-2 Proteins 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
230000007082 Aβ accumulation Effects 0.000 description 2
102100021257 Beta-secretase 1 Human genes 0.000 description 2
102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 2
102000055006 Calcitonin Human genes 0.000 description 2
108060001064 Calcitonin Proteins 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
241000252203 Clupea harengus Species 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
102400000921 Gastrin Human genes 0.000 description 2
108010052343 Gastrins Proteins 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102000005720 Glutathione transferase Human genes 0.000 description 2
108010070675 Glutathione transferase Proteins 0.000 description 2
101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
108091092195 Intron Proteins 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
238000012347 Morris Water Maze Methods 0.000 description 2
241000713333 Mouse mammary tumor virus Species 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
206010029350 Neurotoxicity Diseases 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
206010062519 Poor quality sleep Diseases 0.000 description 2
102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 2
108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000004141 Sodium laurylsulphate Substances 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
101150052863 THY1 gene Proteins 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
206010044221 Toxic encephalopathy Diseases 0.000 description 2
206010044688 Trisomy 21 Diseases 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
108010051583 Ventricular Myosins Proteins 0.000 description 2
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000009858 acid secretion Effects 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
229950006323 angiotensin ii Drugs 0.000 description 2
238000000137 annealing Methods 0.000 description 2
230000000561 anti-psychotic effect Effects 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
210000001130 astrocyte Anatomy 0.000 description 2
230000003190 augmentative effect Effects 0.000 description 2
230000037424 autonomic function Effects 0.000 description 2
230000037429 base substitution Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
229960004015 calcitonin Drugs 0.000 description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000004303 calcium sorbate Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
238000000423 cell based assay Methods 0.000 description 2
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
239000002975 chemoattractant Substances 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000002074 deregulated effect Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000008298 dragée Substances 0.000 description 2
238000009509 drug development Methods 0.000 description 2
239000003596 drug target Substances 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
230000037149 energy metabolism Effects 0.000 description 2
210000004188 enterochromaffin-like cell Anatomy 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
238000000605 extraction Methods 0.000 description 2
229940028334 follicle stimulating hormone Drugs 0.000 description 2
230000037406 food intake Effects 0.000 description 2
235000012631 food intake Nutrition 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
206010017758 gastric cancer Diseases 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
210000001654 germ layer Anatomy 0.000 description 2
210000002149 gonad Anatomy 0.000 description 2
239000000745 gonadal hormone Substances 0.000 description 2
239000003163 gonadal steroid hormone Substances 0.000 description 2
235000019514 herring Nutrition 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000000971 hippocampal effect Effects 0.000 description 2
101150113423 hisD gene Proteins 0.000 description 2
230000003284 homeostatic effect Effects 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
239000000960 hypophysis hormone Substances 0.000 description 2
229960001680 ibuprofen Drugs 0.000 description 2
238000012750 in vivo screening Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
208000000509 infertility Diseases 0.000 description 2
230000036512 infertility Effects 0.000 description 2
231100000535 infertility Toxicity 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000023404 leukocyte cell-cell adhesion Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
229940040129 luteinizing hormone Drugs 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000013011 mating Effects 0.000 description 2
230000035800 maturation Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
210000003643 myeloid progenitor cell Anatomy 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
230000007135 neurotoxicity Effects 0.000 description 2
231100000228 neurotoxicity Toxicity 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
210000001711 oxyntic cell Anatomy 0.000 description 2
239000002245 particle Substances 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
108010040003 polyglutamine Proteins 0.000 description 2
229920000155 polyglutamine Polymers 0.000 description 2
239000004302 potassium sorbate Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
210000004129 prosencephalon Anatomy 0.000 description 2
238000012340 reverse transcriptase PCR Methods 0.000 description 2
238000007423 screening assay Methods 0.000 description 2
210000000582 semen Anatomy 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
235000020183 skimmed milk Nutrition 0.000 description 2
239000012453 solvate Substances 0.000 description 2
230000008010 sperm capacitation Effects 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000003270 steroid hormone Substances 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
239000000126 substance Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000013589 supplement Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
230000005062 synaptic transmission Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000014621 translational initiation Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
239000004474 valine Substances 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
238000011714 129 mouse Methods 0.000 description 1
UDOGNMDURIJYQC-UHFFFAOYSA-N 2-amino-6-methyl-1h-pteridin-4-one Chemical compound N1C(N)=NC(=O)C2=NC(C)=CN=C21 UDOGNMDURIJYQC-UHFFFAOYSA-N 0.000 description 1
CIUICCYYGROKEM-UHFFFAOYSA-N 2h-phenanthren-3-one Chemical compound C1=CC=C2C3=CC(=O)CC=C3C=CC2=C1 CIUICCYYGROKEM-UHFFFAOYSA-N 0.000 description 1
239000005725 8-Hydroxyquinoline Substances 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000018282 ACys amyloidosis Diseases 0.000 description 1
206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
102000009346 Adenosine receptors Human genes 0.000 description 1
108050000203 Adenosine receptors Proteins 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
206010059245 Angiopathy Diseases 0.000 description 1
102100029470 Apolipoprotein E Human genes 0.000 description 1
101710095339 Apolipoprotein E Proteins 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
101100191765 Arabidopsis thaliana PBD2 gene Proteins 0.000 description 1
241000700107 Beroe Species 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
240000001432 Calendula officinalis Species 0.000 description 1
235000005881 Calendula officinalis Nutrition 0.000 description 1
235000009467 Carica papaya Nutrition 0.000 description 1
208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
108010004103 Chylomicrons Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
101710095468 Cyclase Proteins 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
208000031124 Dementia Alzheimer type Diseases 0.000 description 1
108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
101710087092 Dipeptidyl-peptidase 5 Proteins 0.000 description 1
102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 1
244000290594 Ficus sycomorus Species 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
206010064571 Gene mutation Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
206010019375 Helicobacter infections Diseases 0.000 description 1
241000590002 Helicobacter pylori Species 0.000 description 1
208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
101001026885 Homo sapiens Serine/threonine-protein kinase D3 Proteins 0.000 description 1
101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
208000027747 Kennedy disease Diseases 0.000 description 1
ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
SCBLXQAXDOWFIH-ZDUSSCGKSA-N L-glutamine 2-naphthylamide Chemical compound C1=CC=CC2=CC(NC(=O)[C@H](CCC(N)=O)N)=CC=C21 SCBLXQAXDOWFIH-ZDUSSCGKSA-N 0.000 description 1
ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
208000007466 Male Infertility Diseases 0.000 description 1
101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
LRJUYAVTHIEHAI-LHBNDURVSA-N Muristerone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H]([C@H](O)C[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)C)CC[C@]33O)C)C3=CC(=O)[C@@]21O LRJUYAVTHIEHAI-LHBNDURVSA-N 0.000 description 1
101100480715 Mus musculus Mapt gene Proteins 0.000 description 1
102000005604 Myosin Heavy Chains Human genes 0.000 description 1
HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
102000008763 Neurofilament Proteins Human genes 0.000 description 1
108010088373 Neurofilament Proteins Proteins 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
206010033885 Paraparesis Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
102000006877 Pituitary Hormones Human genes 0.000 description 1
108010047386 Pituitary Hormones Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
235000019484 Rapeseed oil Nutrition 0.000 description 1
101001058233 Rattus norvegicus Gamma-enolase Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108700005075 Regulator Genes Proteins 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
101710084578 Short neurotoxin 1 Proteins 0.000 description 1
241000710960 Sindbis virus Species 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
108010052164 Sodium Channels Proteins 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
101710182532 Toxin a Proteins 0.000 description 1
101710195626 Transcriptional activator protein Proteins 0.000 description 1
102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
239000005862 Whey Substances 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
210000005221 acidic domain Anatomy 0.000 description 1
230000030120 acrosome reaction Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000003281 allosteric effect Effects 0.000 description 1
UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
230000006933 amyloid-beta aggregation Effects 0.000 description 1
230000003942 amyloidogenic effect Effects 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
238000003975 animal breeding Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
210000003295 arcuate nucleus Anatomy 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
239000003693 atypical antipsychotic agent Substances 0.000 description 1
229940127236 atypical antipsychotics Drugs 0.000 description 1
230000006399 behavior Effects 0.000 description 1
238000009227 behaviour therapy Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000007321 biological mechanism Effects 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
230000004641 brain development Effects 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
230000003491 cAMP production Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000008045 co-localization Effects 0.000 description 1
230000003931 cognitive performance Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
210000003618 cortical neuron Anatomy 0.000 description 1
238000009402 cross-breeding Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
230000035622 drinking Effects 0.000 description 1
239000006196 drop Substances 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000002367 endolytic effect Effects 0.000 description 1
108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000008556 epithelial cell proliferation Effects 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
108010072257 fibroblast activation protein alpha Proteins 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
108091006047 fluorescent proteins Proteins 0.000 description 1
102000034287 fluorescent proteins Human genes 0.000 description 1
230000003325 follicular Effects 0.000 description 1
230000037433 frameshift Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000012215 gene cloning Methods 0.000 description 1
238000003209 gene knockout Methods 0.000 description 1
238000003208 gene overexpression Methods 0.000 description 1
238000010363 gene targeting Methods 0.000 description 1
238000010362 genome editing Methods 0.000 description 1
230000009688 glial response Effects 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000002710 gonadal effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000005090 green fluorescent protein Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
229940037467 helicobacter pylori Drugs 0.000 description 1
238000013537 high throughput screening Methods 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
102000046783 human APP Human genes 0.000 description 1
102000046768 human CCL2 Human genes 0.000 description 1
102000057063 human MAPT Human genes 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
239000000601 hypothalamic hormone Substances 0.000 description 1
229940043650 hypothalamic hormone Drugs 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000012405 in silico analysis Methods 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000009399 inbreeding Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000006317 isomerization reaction Methods 0.000 description 1
238000011819 knockout animal model Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
229920005610 lignin Polymers 0.000 description 1
230000006742 locomotor activity Effects 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
210000003442 median eminence Anatomy 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
210000000274 microglia Anatomy 0.000 description 1
210000004939 midgestation embryo Anatomy 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
230000009125 negative feedback regulation Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
230000000955 neuroendocrine Effects 0.000 description 1
210000005044 neurofilament Anatomy 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
231100000189 neurotoxic Toxicity 0.000 description 1
230000002887 neurotoxic effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
238000010606 normalization Methods 0.000 description 1
230000005257 nucleotidylation Effects 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000009437 off-target effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000008520 organization Effects 0.000 description 1
238000009400 out breeding Methods 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
229960003540 oxyquinoline Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000004963 pathophysiological condition Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
238000011170 pharmaceutical development Methods 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229940012982 picot Drugs 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
108010055896 polyornithine Proteins 0.000 description 1
229920002714 polyornithine Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
210000004258 portal system Anatomy 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
201000011461 pre-eclampsia Diseases 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000000135 prohibitive effect Effects 0.000 description 1
230000001915 proofreading effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000004853 protein function Effects 0.000 description 1
230000012743 protein tagging Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
230000006340 racemization Effects 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
102200061534 rs63750526 Human genes 0.000 description 1
QSHGUCSTWRSQAF-FJSLEGQWSA-N s-peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C1=CC=C(OS(O)(=O)=O)C=C1 QSHGUCSTWRSQAF-FJSLEGQWSA-N 0.000 description 1
230000000698 schizophrenic effect Effects 0.000 description 1
210000004739 secretory vesicle Anatomy 0.000 description 1
230000007507 senile plaque formation Effects 0.000 description 1
208000022288 senile plaque formation Diseases 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
230000036299 sexual function Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000007470 synaptic degeneration Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000563 toxic property Toxicity 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
229910001428 transition metal ion Inorganic materials 0.000 description 1
238000013519 translation Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1
210000004340 zona pellucida Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Environmental Sciences (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Biodiversity & Conservation Biology (AREA)
Plant Pathology (AREA)
Animal Husbandry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)

CA2710494A 2008-01-14 2009-01-14 Modeles murins portant une mutation du type inactivation du gene de la glutaminyl cyclase Abandoned CA2710494A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2078408P	2008-01-14	2008-01-14
US61/020,784		2008-01-14
PCT/EP2009/050387 WO2009090190A1 (fr)	2008-01-14	2009-01-14	Modèles murins portant une mutation du type inactivation du gène de la glutaminyl cyclase

Publications (1)

Publication Number	Publication Date
CA2710494A1 true CA2710494A1 (fr)	2009-07-23

Family

ID=40427980

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2710494A Abandoned CA2710494A1 (fr)	2008-01-14	2009-01-14	Modeles murins portant une mutation du type inactivation du gene de la glutaminyl cyclase

Country Status (9)

Country	Link
US (1)	US9462793B2 (fr)
EP (1)	EP2238252B1 (fr)
JP (1)	JP2011511622A (fr)
AU (1)	AU2009204864A1 (fr)
CA (1)	CA2710494A1 (fr)
IL (1)	IL206484A0 (fr)
NZ (1)	NZ586665A (fr)
WO (1)	WO2009090190A1 (fr)
ZA (1)	ZA201004367B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2017524382A (ja) *	2014-08-01	2017-08-31	ザ・ジョンズ・ホプキンス・ユニバーシティー	偽アレルギー薬物反応を検出するためおよび有害反応を予防する遮断薬を同定するためのｍｒｇｐｒｘ２／ｍｒｇｐｒｂ２発現細胞ベースのアッセイ

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4873191A (en)	1981-06-12	1989-10-10	Ohio University	Genetic transformation of zygotes
EP0264166B1 (fr)	1986-04-09	1996-08-21	Genzyme Corporation	Animaux transformés génétiquement sécrétant une protéine désirée dans le lait
US4873316A (en) *	1987-06-23	1989-10-10	Biogen, Inc.	Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5175384A (en) *	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8901778D0 (en)	1989-01-27	1989-03-15	Univ Court Of The University O	Manipulatory technique
US5602299A (en) *	1992-09-23	1997-02-11	Mount Sinai School Of Medicine Of The City University Of New York	Transgenic animal models for neurodegenerative disease
JPH07132033A (ja) *	1993-11-12	1995-05-23	Hoechst Japan Ltd	アルツハイマー病モデルトランスジェニック動物
US6066778A (en) *	1996-11-06	2000-05-23	The Regents Of The University Of Michigan	Transgenic mice expressing APC resistant factor V
US5981830A (en) *	1997-05-30	1999-11-09	Schering Aktiengesellschaft	Knockout mice and their progeny with a disrupted hepsin gene
US20030013177A1 (en) *	2001-05-23	2003-01-16	Ebens Allen J.	Polynucleotides encoding insect glutaminyl cyclase and uses thereof
US6948038B2 (en) *	2001-07-24	2005-09-20	Microsoft Corporation	System and method for backing up and restoring data
US8338120B2 (en) *	2003-05-05	2012-12-25	Probiodrug Ag	Method of treating inflammation with glutaminyl cyclase inhibitors
DE602004026712D1 (de) *	2003-05-05	2010-06-02	Probiodrug Ag	Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen
ZA200508439B (en) *	2003-05-05	2007-03-28	Probiodrug Ag	Medical use of inhibitors of glutaminyl and glutamate cyclases
US7732162B2 (en) *	2003-05-05	2010-06-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
CN1784220B (zh)	2003-05-05	2011-08-03	前体生物药物股份公司	谷氨酰胺酰基和谷氨酸环化酶效应物的应用
CN102302781A (zh)	2003-10-15	2012-01-04	前体生物药物股份公司	谷氨酰胺酰基环化酶效应物和谷氨酸环化酶效应物的应用
EP2338490A3 (fr) *	2003-11-03	2012-06-06	Probiodrug AG	Combinaisons utiles pour le traitement de désordres neuronales
US7667044B2 (en) *	2003-11-03	2010-02-23	Probiodrug Ag	Compounds for the treatment of neurological disorders
US20050171112A1 (en) *	2003-11-03	2005-08-04	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
EP1713780B1 (fr) *	2004-02-05	2012-01-18	Probiodrug AG	Nouveaux inhibiteurs de la glutaminyl-cyclase
EP2082041B1 (fr)	2006-09-21	2018-03-14	Probiodrug AG	Gènes innovants liés à la glutaminyl-cyclase
EP2086960B1 (fr) *	2006-11-09	2014-03-05	Probiodrug AG	Nouveaux inhibiteurs de la glutaminyl-cyclase
US8420684B2 (en) *	2006-11-09	2013-04-16	Probiodrug Ag	Inhibitors of glutaminyl cyclase
SI2091948T1 (sl) *	2006-11-30	2012-07-31	Probiodrug Ag	Novi inhibitorji glutaminil ciklaze
NZ578513A (en) *	2007-01-19	2012-01-12	Probiodrug Ag	In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders
JP5612860B2 (ja) *	2007-03-09	2014-10-22	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤としてのイミダゾ［１，５−ａ］ピリジン誘導体
ES2478673T3 (es) *	2007-04-18	2014-07-22	Probiodrug Ag	Derivados de tioxoquinazolinona como inhibidores de la glutaminil ciclasa
JP5675343B2 (ja) *	2007-04-18	2015-02-25	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤としての尿素誘導体
DK2142513T3 (da) *	2007-04-18	2014-06-10	Probiodrug Ag	Nitrovinyl-diamin-derivater som glutaminyl-cyclase-inhibitorer
DK2160380T3 (da) *	2007-04-18	2014-06-30	Probiodrug Ag	Cyano-guanidin derivater som glutaminyl cyclase inhibitorer
EP2865670B1 (fr) *	2007-04-18	2017-01-11	Probiodrug AG	Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
DK2142515T3 (da) *	2007-04-18	2014-06-23	Probiodrug Ag	Nitrovinyl-diaminderivater som glutaminyl-cyclase-inhibitorer
EP2142536B1 (fr) *	2007-04-20	2015-10-21	Probiodrug AG	Dérivés d'aminopyrimidine utilisés comme inhibiteurs de la glutaminyl cyclase
CA2696934A1 (fr) *	2007-09-12	2010-02-16	Probiodrug Ag	Souris transgeniques

2009
- 2009-01-14 WO PCT/EP2009/050387 patent/WO2009090190A1/fr not_active Ceased
- 2009-01-14 EP EP09702062.2A patent/EP2238252B1/fr not_active Not-in-force
- 2009-01-14 JP JP2010541803A patent/JP2011511622A/ja active Pending
- 2009-01-14 CA CA2710494A patent/CA2710494A1/fr not_active Abandoned
- 2009-01-14 US US12/353,463 patent/US9462793B2/en not_active Expired - Fee Related
- 2009-01-14 AU AU2009204864A patent/AU2009204864A1/en not_active Abandoned
- 2009-01-14 NZ NZ586665A patent/NZ586665A/en not_active IP Right Cessation
2010
- 2010-06-20 IL IL206484A patent/IL206484A0/en unknown
- 2010-06-21 ZA ZA2010/04367A patent/ZA201004367B/en unknown

Also Published As

Publication number	Publication date
US9462793B2 (en)	2016-10-11
AU2009204864A1 (en)	2009-07-23
IL206484A0 (en)	2010-12-30
EP2238252A1 (fr)	2010-10-13
JP2011511622A (ja)	2011-04-14
US20090183267A1 (en)	2009-07-16
WO2009090190A1 (fr)	2009-07-23
EP2238252B1 (fr)	2013-07-31
NZ586665A (en)	2011-12-22
WO2009090190A9 (fr)	2010-08-26
ZA201004367B (en)	2011-08-31

Publication	Publication Date	Title
US20080200567A1 (en)	2008-08-21	In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders
US8283517B2 (en)	2012-10-09	Transgenic mouse models of Aβ overexpression
US9462793B2 (en)	2016-10-11	Mouse carrying a knock-out mutation of the Qpct-gene
EP2432314B1 (fr)	2017-12-20	Modeles de souris portant une mutation du type inactivation du qpctl-gène
US9277737B2 (en)	2016-03-08	Mouse models carrying a knock-out mutation of the QPCTL-gene
TOWER	2009	Schilling et al.(43) Pub. Date: Jul. 16, 2009
US20150150225A1 (en)	2015-06-04	Transgenic mouse expressing human isoglutaminyl cyclotransferase
US20130052203A1 (en)	2013-02-28	In vivo screening models for treatment of qc-related disorders
Stephan5Halle et al.	0	Demuth et al.(43) Pub. Date: Oct. 31, 2013
Graubner et al.	1969	Graubner
HK1146735A (en)	2011-07-08	Transgenic mice

Legal Events

Date	Code	Title	Description
2015-03-11	FZDE	Discontinued	Effective date: 20150114